SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?


To: scaram(o)uche who wrote (7219)11/22/1999 3:24:00 AM
From: E  Read Replies (1) | Respond to of 9719
 
OT, with apologies for the interruption:

To all: Here is a wonderful site. You might want to visit it daily, and email it to all your friends with the suggestion that they do it, too, and pass it on to their friends. You'll see why if you go there:

thehungersite.com

You simply click the button once a day and your click will have induced a corporate sponsor to donate a specified amount of free food to a hungry person.

The amount of food -- rice, wheat, maize or other staple food -- you send by your click varies according to how many corporations (or, occasionally, individuals) are sponsoring the site that day. Today it is 2 1/4cups. I have seen it as little as 3/4 cup but never higher than 2 1/4 cups. I'm sort of excited about it being up to 2 1/4 cups, because I can't help but wonder whether it's SI people, and all the friends they've emailed about it, and their friends, who are responsible.

Maybe your company would even want to sponsor the site? Each sponsor pays for 1/4 cup of food....

"Every 3.6 seconds someone dies of hunger; 3/4 of the deaths are children under 5."

(Sorry for the interruption!)

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
P.S.

To make the Hunger site your start up page in Netscape
______________________________________________________

click Edit to Preferences

Click Navigator

Select "Navigator starts with": = Home Page

Move down to "Home Page"

At Location, paste in: thehungersite.com



To: scaram(o)uche who wrote (7219)11/22/1999 9:08:00 AM
From: Ward Knutson  Read Replies (1) | Respond to of 9719
 
Richard

<<Not enough to conduct multi-center phase III trials sufficient to target worldwide registration for multiple indications>>

The above is true, this is NOT what V1 said (multiple indications not stated). Without knowing the data they are compiling there is no way you can asses the options available to them. The problem with your blanket statement is neither of you know their development plan nor the data from the clinical trials. They are working on defining registration strategies and it would be reasonable to assume Phase II results would dictate the scope and direction of such a plan. This would also aid in the definition of an appropriate partnership. The need and timing would be more clear when you define your targets. I never stated that they would not partner, I merely am pointing out that as of today there is no need to have the deal inked. They have plenty of resources to aggressively continue the development at this point. You can well imagine the doors that open with a set of highly compelling Phase II data in hand. They will undoubtedly be operating more from a position of strength with strong Phase II information.

<<I guess I expected better initial results in the phase IIs>>

V1 stated the above directly contradicting his earlier enthusiasm for Phase II prostate initial results. Nothing additional has yet to be reported on Phase II, with the exception of increased excitement and optimism for the drug based on long-term treatment of many very ill cancer patients. He made the statement without support.

Lastly, it is reasonable to assume Blitzer could have delivered on his Goal of European Partner, but at what cost? To ink a deal merely to meet a stated goal without consideration for the building knowledge as it relates to the potential for 114 would be a mistake. Is it not within the realm of possibility that Blitzer & company saw early signs of promise which altered the price tag for such deal. Undoubtedly building confidence along the development process would dictate waiting for more conclusive data to be compiled in efforts to make a better partnership deal for the company and shareholders.